Reference number 3047-A

SPECIALTY GUIDELINE MANAGEMENT

SKYRIZI (risankizumab-rzaa)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Moderate to severe plaque psoriasis

- A. Authorization of 12 months may be granted for members who are 18 years of age or older who have previously received Skyrizi, Otezla, or any other biologic DMARD indicated for the treatment of moderate to severe plaque psoriasis.
- B. Authorization of 12 months may be granted for treatment of moderate to severe plaque psoriasis for members who are 18 years of age or older when all of the following criteria are met:
 - 1. At least 5% of body surface area (BSA) is affected OR crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected.
 - 2. Member meets any of the following criteria:
 - a. Member has had an inadequate response to either phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine or acitretin.
 - b. Member has a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine and acitretin (see Appendix).
 - c. Member has severe psoriasis that warrants a biologic DMARD as first-line therapy.

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for all members (including new members) who meet all initial authorization criteria and achieve or maintain positive clinical response after at least 4 months of therapy with Skyrizi as evidenced by low disease activity or improvement in signs and symptoms of the condition.

IV. OTHER

Member has a pretreatment tuberculosis (TB) screening with a TB skin test or an interferon gamma release assay (e.g., QFT-GIT, T-SPOT.TB).

Note: Members who have received Skyrizi or any other biologic DMARD or targeted synthetic DMARD (e.g., Xeljanz) are exempt from requirements related to TB screening in this Policy.

Skyrizi 3047-A SGM P2019

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number	
3047-A	

For all indications: Members cannot use Skyrizi concomitantly with any other biologic DMARD or targeted synthetic DMARD.


V. APPENDIX

Examples of Clinical Reasons to Avoid Pharmacologic Treatment with Methotrexate, Cyclosporine and **Acitretin**

- 1. Alcoholism, alcoholic liver disease or other chronic liver disease
- 2. Breastfeeding
- 3. Cannot be used due to risk of treatment-related toxicity
- 4. Drug interaction
- 5. Pregnancy or planning pregnancy
- 6. Significant comorbidity prohibits use of systemic agents (examples include liver or kidney disease, blood dyscrasias, uncontrolled hypertension)

VI. REFERENCES

- 1. Skyrizi [package insert]. North Chicago, IL: AbbVie Inc.; April 2019.
- 2. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451-485.
- 3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137-174.
- 4. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plague psoriasis (UltIMMa-1 and UltIMMa-2); results from two double-blind, randomised, placebocontrolled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661.



CVS caremark